Format

Send to

Choose Destination
Nutr J. 2017 Jun 29;16(1):39. doi: 10.1186/s12937-017-0261-6.

Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial.

Author information

1
Department of Nutritional Sciences, Pennsylvania State University, 110 Chandlee Laboratory, University Park, PA, 16802, USA.
2
Department of Food Science, Pennsylvania State University, 206 Rodney A. Erickson Food Science Building, University Park, PA, 16802, USA.
3
Department of Nutritional Sciences, Pennsylvania State University, 110 Chandlee Laboratory, University Park, PA, 16802, USA. pmk3@psu.edu.

Abstract

BACKGROUND:

Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent.

OBJECTIVE:

We examined the effects of Bifidobacterium animalis subsp. lactis BB-12® (BB-12®) (3.16 × 109 CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults.

METHODS:

In a randomized, partially blinded, 4-period, crossover study, 30 adults (11 men, 19 women) aged 18-40 years were randomly assigned to: 1) yogurt smoothie with no BB-12® (YS), 2) yogurt smoothie with BB-12® added pre-fermentation (PRE), 3) yogurt smoothie with BB-12® added post-fermentation (POST), 4) BB-12® containing capsule (CAP). We measured serum lipids/lipoproteins, glucose, insulin, C-reactive protein (CRP), and fecal SCFAs at baseline and after each treatment period.

RESULTS:

Total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TGs) did not differ after the PRE, POST, and CAP periods versus the YS or between treatments. Compared to baseline, fecal acetate was significantly increased after the YS (Δ = 211.89 ± 75.87 μg/g, P = 0.007) and PRE (Δ = 204.98 ± 75.70 μg/g, P = 0.009) periods. The percent increase in fecal acetate was significantly greater after the YS versus the POST period (52.2 ± 13.2% vs. 24.5 ± 13.2%, P = 0.023). Fecal total SCFAs, propionate and butyrate did not differ between treatment periods. Fecal total SCFAs were negatively associated with TC (r = -0.22, P = 0.01), LDL-C (r = -0.24, P = 0.004), age (r = -0.33, P < 0.001), and waist circumference (r = -0.25, P = 0.003).

CONCLUSIONS:

BB-12® supplementation did not improve lipids, lipoproteins and total and individual fecal SCFAs. Fecal SCFAs were negatively associated with TC, LDL-C, age, and waist circumference.

TRIAL REGISTRATION:

This trial was registered at clinicaltrials.gov as NCT01399996 .

KEYWORDS:

BB-12; Lipids; Lipoproteins; Probiotics; SCFAs; Waist circumference

PMID:
28662676
PMCID:
PMC5492721
DOI:
10.1186/s12937-017-0261-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center